Nasus Pharma Ltd.
NSRX | AMEX
$3.16
-$0.15 (-4.53%)
At close: Oct 30, 2026, 3:59 PM ET
$3.16
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 3:59 PM ET
Company Profile
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Key Executives
| Name | Position |
|---|---|
| Brendan O'Grady | Chief Executive Officer & Director |
| Dalia Megiddo | Co-Founder, Director, Chief Medical Officer & Chief Development Officer? |
| Ehud Moshe Gilboa | Co-Founder & Executive Chairman |
| Eyal Rubin | CFO & Executive VP |
| Galia Temtsin Kryaz | Director of CMC & Product Development |
| Oren Elmaliach | Director of Finance & Interim CFO |
| Yifat Bar | Vice President of Administration & Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 23, 2026 | 3 | Filing |
| Sep 21, 2026 | 4 | Filing |
| Sep 18, 2026 | 424B5 | Filing |
| Sep 18, 2026 | 6-K | Filing |
| Sep 14, 2026 | 6-K | Filing |
| Sep 11, 2026 | EFFECT | Filing |
| Sep 04, 2026 | 6-K | Filing |
| Sep 01, 2026 | F-3 | Filing |
| Aug 20, 2026 | EFFECT | Filing |
| Aug 19, 2026 | 6-K | Filing |
Nasus Pharma Ltd.
| Country | Israel |
| IPO Date | Aug 13, 2025 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Brendan O'Grady |
Stock Details
| Ticker Symbol | NSRX |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002029039 |
| CUSIP Number | n/a |
| ISIN Number | IL0012181553 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove NSRX